Dr James L Januzzi
Cardiologist, Massachusetts General Hospital. Prof of Medicine, Harvard Medical School

Natriuretic Peptide Measurement during ARNi Treatment


  • Treatment with ARNi results in a rise of many vasoactive peptides such as BNP, ANP etc.
  • Being a target of neprilysin metabolism, BNP can be raised in patients on ARNi which is not reflective of an adverse prognosis
  • NT-proBNP is not a substrate of neprilysin and hence its levels in Heart Failure patients treated with ARNi is reflective of a good prognosis and cardiac remodelling
  • NT-proBNP is the preferred cardiac biomarker for monitoring treatment with ARNi

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy. [...]


CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi